Plain-English translation of NCT06862700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following 534 adults who are receiving a temporary heart-lung machine (called VA-ECMO) because their heart cannot pump strongly enough on its own. Researchers want to understand whether patients who receive lower doses of blood pressure-supporting medications have better outcomes than those receiving higher doses. The study will track survival rates, hospital recovery, and complications over 30 days.
When patients are on a heart-lung machine, doctors use strong medications to support blood pressure and help the heart. However, it's unclear whether using lower doses of these medications—while still keeping patients stable—might actually help them survive longer and recover better. This study aims to find the safest and most effective approach to managing these patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive your standard medical care in the intensive care unit while on the heart-lung machine. Doctors will monitor your blood pressure medications, heart function, and blood work regularly—this is part of routine care. Researchers will collect data about your medication doses, vital signs, and outcomes over your hospital stay, with the main focus being whether you survive the first 30 days.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Xiaotong Hou
Enrollment target
~534 participants
Started
February 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaotong Hou, MD
Beijing Anzhen Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.